Why BioNTech (BNTX) Shares Are Trading Lower Today - BioNTech (NASDAQ:BNTX)

BioNTech SE BNTX has reported Q3 FY22 revenues of €3.46 billion, down from €6.09 billion a year ago, blaming the dynamic course of the pandemic leading to fluctuations in quarterly revenues.
The company posted diluted EPS of €6.98, down from €12.35 a year ago.
The company has invoiced approximately 300 million doses of the original/omicron BA.1- and BA.4/BA.5-adapted bivalent vaccines as of mid-October 2022.
Ugur Sahin, BioNTech's co-founder & CEO, said, "The next chapter of BioNTech's evolution is becoming tangible; we continue to expand our COVID-19 vaccine and infectious disease portfolio and advance our oncology pipeline."
Related: BioNTech's COVID-19 Vaccine Becomes First Foreign Shot To Be Available In Chinese Market.
Outlook: BioNTech has raised its COVID-19 vaccine revenue estimate to the upper end of the original range: €16 - 17 billion (previously: €13 - 17 billion).
The updated guidance reflects the shipment of the Omicron-adapted bivalent vaccine boosters, which started early in September and is expected to continue throughout the fourth quarter of 2022, as well as higher prices and a favorable foreign currency effect.
Price Action: BNTX shares are down 4.41% at $147.51 during the premarket session on the last check Monday.

Momentum53.41

GrowthNot Available

QualityNot Available

Value55.95

Short

Medium

Long

BioNTech Posts About 50% Drop In Q3 Sales and Profits Amid Falling Demand For COVID-19 Shots